Trial Profile
Searching for the Optimal Regimen of Potent P2Y12 Inhibitor in East Asian Patients with Acute Coronary Syndrome: A Pharmacodynamic Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2015
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Pharmacodynamics
- 26 Aug 2015 New trial record